{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:00:08Z","timestamp":1792674008904,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2009<\/jats:title>\n                  <jats:p>The kidneys produce daily about 180 liters of urine but only about 2 liters are excreted. The proximal tubule plays an important role in reabsorbing the majority of filtered urine and many metabolites such as sugars, amino acids, salts or phosphate that are contained in this large volume. Reabsorption of these important metabolites is mediated by a diverse group of highly specialized transport proteins. Another group of transport proteins in the proximal tubule is responsible for the active secretion of metabolic waste products or toxins and drugs into urine. All these transporters have in common that they are directly linked to kidney metabolism and indirectly to whole-body metabolism and functions. In recent years, it has become evident that modulation of these transporters may influence the onset, progression and consequences of kidney disease. This review summarizes recent developments in this field and discusses some examples of drugs already in clinical use or in development. The examples include inhibitors of sugar transporters (SGLT2 inhibitors) that are successfully used in patients with kidney disease, diabetes or heart failure. Likewise, indirect inhibitors (acetazolamide) of an transporter absorbing sodium in exchange for protons (NHE3) are used mostly in patients with heart failure or for prevention of high altitude disease, while direct inhibitors show promise in preclinical studies to reduce damage in episodes of acute kidney disease or high blood pressure. Modulators of transporters mediating the excretion of urate have been used in patients with gout and are also discussed to prevent kidney disease. Novel drugs in development target transporters for phosphate, amino acids, or toxin and drug excretion and may be helpful for specific conditions associated with kidney disease. The advantages and challenges associated with these (novel) drugs targeting proximal tubule transport are discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The proximal tubule is responsible for reabsorbing about 60% of filtered solutes and water and is critical for the secretion of metabolic waste products, drugs and toxins. A large number of highly specialized ion channels and transport proteins belonging to the SLC and ABC transporter families are involved. Their activity is directly or indirectly linked to ATP consumption and requires large quantities of energy and oxygen supply. Moreover, the activity of these transporters is often coupled to the movement of Na+ ions thus influencing also salt and water balance, as well as transport and regulatory processes in downstream segments. Because of their relevance for systemic ion balance, for renal metabolism or for affecting regulatory processes, proximal tubule transporters are attractive targets for existing drug and for novel strategies to reduce kidney disease progression or to alleviate the consequences of decreased kidney function. In this review, the relevance of some major proximal tubule transport systems as drug targets in individuals with chronic kidney disease (CKD) is discussed. Inhibitors of the sodium-glucose cotransporter 2, SGLT2, are now part of standard therapy in patients with CKD and\/or heart failure. Also, indirect inhibition of Na+\/H+-exchangers by carbonic anhydrase inhibitors and uricosuric drugs have been used for decades. Inhibition of phosphate and amino acid transporters have recently been proposed as novel principles to remove excess phosphate or to protect the proximal tubule metabolically, respectively. In addition, organic cation and anion transporters involved in drug and toxin excretion may serve as targets of new drugs. The advantages and challenges associated with (novel) drugs targeting proximal tubule transport are discussed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae211","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T19:21:45Z","timestamp":1726860105000},"page":"i18-i28","source":"Crossref","is-referenced-by-count":18,"title":["Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-8898","authenticated-orcid":false,"given":"Carsten A","family":"Wagner","sequence":"first","affiliation":[{"name":"University of Zurich \u2013 Institute of Physiology , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025020513212293700_bib1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/cphy.c100073","article-title":"Uriniferous tubule: structural and functional organization","volume":"2","author":"Christensen","year":"2012","journal-title":"Compr Physiol"},{"key":"2025020513212293700_bib2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"2025020513212293700_bib3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","article-title":"How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?","volume":"39","author":"Vallon","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513212293700_bib4","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.15420\/cfr.2022.11","article-title":"Clinical evidence and proposed mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a class effect?","volume":"8","author":"Deschaine","year":"2022","journal-title":"Card Fail Rev"},{"key":"2025020513212293700_bib5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41584-024-01092-x","article-title":"The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout","volume":"20","author":"Yokose","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025020513212293700_bib6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2025020513212293700_bib7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/jdi.12473","article-title":"Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy","volume":"7","author":"Osaki","year":"2016","journal-title":"J Diabetes Invest"},{"key":"2025020513212293700_bib8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.2337\/dc21-0300","article-title":"Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"key":"2025020513212293700_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513212293700_bib10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2025020513212293700_bib11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"2025020513212293700_bib12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"2025020513212293700_bib13","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers","volume":"9","author":"Lee","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025020513212293700_bib14","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.3390\/ijerph20176671","article-title":"Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging","volume":"20","author":"Sch\u00f6nberger","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"2025020513212293700_bib15","doi-asserted-by":"publisher","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025020513212293700_bib16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00424-024-02937-w","article-title":"The role of Na+ coupled bicarbonate transporters (NCBT) in health and disease","volume":"476","author":"Holmberg","year":"2024","journal-title":"Pflugers Arch"},{"key":"2025020513212293700_bib17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00424-024-02938-9","article-title":"New functions and roles of the Na+-H+-exchanger NHE3","volume":"476","author":"Dominguez Rieg","year":"2024","journal-title":"Pflugers Arch"},{"key":"2025020513212293700_bib18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.119.13094","article-title":"Proximal tubule-specific deletion of the NHE3 (Na(+)\/H(+) Exchanger 3) in the kidney attenuates Ang II (angiotensin II)-induced hypertension in mice","volume":"74","author":"Li","year":"2019","journal-title":"Hypertension"},{"key":"2025020513212293700_bib19","first-page":"467","article-title":"Acetazolamide-associated acute kidney injury in critically Ill pediatric patients","volume":"26","author":"Moffett","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025020513212293700_bib20","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","article-title":"Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial","volume":"44","author":"Meekers","year":"2023","journal-title":"Eur Heart J"},{"key":"2025020513212293700_bib21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2025020513212293700_bib22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40620-023-01850-2","article-title":"Acetazolamide for acute kidney injury in patients undergoing high dose methotrexate therapy: a systematic review and meta-analysis","volume":"37","author":"Truong","year":"2024","journal-title":"J Nephrol"},{"key":"2025020513212293700_bib23","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1046\/j.1523-1755.2001.00058.x","article-title":"S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats","volume":"60","author":"Hropot","year":"2001","journal-title":"Kidney Int"},{"key":"2025020513212293700_bib24","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025020513212293700_bib25","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","article-title":"Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review","volume":"83","author":"Terkeltaub","year":"2023","journal-title":"Drugs"},{"key":"2025020513212293700_bib26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ckj\/sfaa236","article-title":"The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality","volume":"13","author":"Gonzalez-Martin","year":"2020","journal-title":"Clin Kidney J"},{"key":"2025020513212293700_bib27","article-title":"Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025020513212293700_bib28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00424-020-02370-9","article-title":"Expression of NaPi-IIb in rodent and human kidney and upregulation in a model of chronic kidney disease","volume":"472","author":"Motta","year":"2020","journal-title":"Pflugers Arch"},{"key":"2025020513212293700_bib29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00424-013-1418-6","article-title":"The SLC34 family of sodium-dependent phosphate transporters","volume":"466","author":"Wagner","year":"2014","journal-title":"Pflugers Arch"},{"key":"2025020513212293700_bib30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41581-019-0159-y","article-title":"Mechanisms of phosphate transport","volume":"15","author":"Levi","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025020513212293700_bib31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00008.2019","article-title":"Phosphate transport in epithelial and nonepithelial tissue","volume":"101","author":"Hernando","year":"2021","journal-title":"Physiol Rev"},{"key":"2025020513212293700_bib32","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1073\/pnas.95.9.5372","article-title":"Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities","volume":"95","author":"Beck","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025020513212293700_bib33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00424-008-0530-5","article-title":"Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption","volume":"457","author":"Nowik","year":"2008","journal-title":"Pflugers Arch"},{"key":"2025020513212293700_bib34","doi-asserted-by":"publisher","first-page":"F833","DOI":"10.1152\/ajprenal.00133.2013","article-title":"Renal-specific and inducible depletion of NaPi-IIc\/Slc34a3, the cotransporter mutated in HHRH, does not affect phosphate or calcium homeostasis in mice","volume":"306","author":"Myakala","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212293700_bib35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2008020177","article-title":"Type IIc sodium-dependent phosphate transporter regulates calcium metabolism","volume":"20","author":"Segawa","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl","key":"2025020513212293700_bib36","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"2025020513212293700_bib37","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025020513212293700_bib38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jacc.2011.03.069","article-title":"Vitamin D, parathyroid hormone, and cardiovascular events among older adults","volume":"58","author":"Kestenbaum","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2025020513212293700_bib39","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025020513212293700_bib40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cca.2017.09.005","article-title":"Phosphorus and mortality risk in end-stage renal disease: a meta-analysis","volume":"474","author":"Hou","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2025020513212293700_bib41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2025020513212293700_bib42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1021\/acsmedchemlett.8b00013","article-title":"Discovery of orally bioavailable selective inhibitors of the sodium-phosphate cotransporter NaPi2a (SLC34A1)","volume":"9","author":"Filipski","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2025020513212293700_bib43","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1172\/JCI135665","article-title":"Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion","volume":"130","author":"Clerin","year":"2020","journal-title":"J Clin Invest"},{"key":"2025020513212293700_bib44","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1681\/ASN.2018121250","article-title":"Pharmacological Npt2a inhibition causes phosphaturia and reduces plasma phosphate in mice with normal and reduced kidney function","volume":"30","author":"Thomas","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025020513212293700_bib45","doi-asserted-by":"publisher","first-page":"F541","DOI":"10.1152\/ajprenal.00146.2020","article-title":"PF-06869206 is a selective inhibitor of renal Pi transport: evidence from in vitro and in vivo studies","volume":"319","author":"Thomas","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212293700_bib46","doi-asserted-by":"publisher","first-page":"iii154","DOI":"10.1093\/ndt\/gfaa140.MO053","article-title":"Inhibition of soidum phosphate transporter NPT2a improves experimental vascular calcification and phosphate homeostasis in rats (abstract)","volume":"35","author":"Klar","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513212293700_bib47","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025020513212293700_bib48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2025020513212293700_bib49","doi-asserted-by":"publisher","first-page":"F584","DOI":"10.1152\/ajprenal.2000.279.3.F584","article-title":"Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2","volume":"279","author":"Wagner","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513212293700_bib50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2133\/dmpk.23.236","article-title":"Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity","volume":"23","author":"Kamal","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025020513212293700_bib51","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.xphs.2017.04.076","article-title":"The Effect of uremic solutes on the organic cation transporter 2","volume":"106","author":"Cheung","year":"2017","journal-title":"J Pharm Sci"},{"key":"2025020513212293700_bib52","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.3390\/ijms22126439","article-title":"In vitro inhibition of renal OCT2 and MATE1 secretion by antiemetic drugs","volume":"22","author":"George","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025020513212293700_bib53","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1128\/AAC.01471-16","article-title":"Moxifloxacin is a potent in vitro inhibitor of OCT- and MATE-mediated transport of metformin and ethambutol","volume":"60","author":"Te Brake","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020513212293700_bib54","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.3390\/molecules28135252","article-title":"Research methods and new advances in drug-drug interactions mediated by renal transporters","volume":"28","author":"Lin","year":"2023","journal-title":"Molecules"},{"key":"2025020513212293700_bib55","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1021\/jm301302s","article-title":"Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling","volume":"56","author":"Wittwer","year":"2013","journal-title":"J Med Chem"},{"key":"2025020513212293700_bib56","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Gutierrez","year":"2014","journal-title":"AIDS Rev"},{"key":"2025020513212293700_bib57","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/nature05475","article-title":"Essential role for collectrin in renal amino acid transport","volume":"444","author":"Danilczyk","year":"2006","journal-title":"Nature"},{"key":"2025020513212293700_bib58","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1152\/physrev.00018.2006","article-title":"Amino acid transport across mammalian intestinal and renal epithelia","volume":"88","author":"Br\u00f6er","year":"2008","journal-title":"Physiol Rev"},{"key":"2025020513212293700_bib59","doi-asserted-by":"publisher","first-page":"128421","DOI":"10.1016\/j.bmcl.2021.128421","article-title":"Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B(0)AT1 (SLC6A19)","volume":"53","author":"Desai","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"2025020513212293700_bib60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fphar.2020.00140","article-title":"Novel chemical scaffolds to inhibit the neutral amino acid transporter B(0)AT1 (SLC6A19), a potential target to treat metabolic diseases","volume":"11","author":"Yadav","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025020513212293700_bib61","doi-asserted-by":"publisher","first-page":"e121762","DOI":"10.1172\/jci.insight.121762","article-title":"Inhibiting neutral amino acid transport for the treatment of phenylketonuria","volume":"3","author":"Belanger","year":"2018","journal-title":"JCI Insight"},{"key":"2025020513212293700_bib62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jimd.12568","article-title":"Excretion of excess nitrogen and increased survival by loss of SLC6A19 in a mouse model of ornithine transcarbamylase deficiency","volume":"46","author":"Belanger","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"2025020513212293700_bib63","doi-asserted-by":"publisher","first-page":"F455","DOI":"10.1152\/ajprenal.00181.2022","article-title":"Aristolochic acid-induced nephropathy is attenuated in mice lacking the neutral amino acid transporter B(0)AT1 (Slc6a19)","volume":"323","author":"Navarro Garrido","year":"2022","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i18\/61766459\/gfae211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i18\/61766459\/gfae211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:24:18Z","timestamp":1738761858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i18\/8002196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":63,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae211","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}